Clinical trials: PET/CT
Breast Cancer, Prostate Cancer
68Ga-RM26-RGD PET/CT Imaging in the GRPR and αvβ3 Positive Tumor Patients
Based on the high expression of specific receptors on the surface of diseased tissues and neovascularization, noninvasive targeted molecular imaging can be used to visualize lesions in vitro by combining specific ligands labeled…
- Conditions
- Breast Cancer, Prostate Cancer, Brain Tumor, PET/CT Imaging
- Trial name
- NCT05549024
- Testing
- 68Ga-RM26-RGD, 18F-FDG, 68Ga-RM26
- Where
- China
- Volunteers
- 90 people
- Sponsor
- Peking Union Medical College Hospital
Oncology
Evaluation of a New Generation of PET-CT OMNI
The overarching purpose of the study is to provide supporting evidence to the value proposition of OMNI, that offers global access to an affordable hybrid PET/CT system similar in performance to that of systems utilized by…
- Trial name
- NCT05154877
- Testing
- OMNI PET/CT Scan
- Where
- France
- Volunteers
- 45 people
- Sponsor
- GE Healthcare
Prostate Cancer
PSMA Response in Metastasized Hormone Sensitive Prostate Cancer
PSMA-PET/CT response measurements after LHRH agonist and upfront therapy in men diagnosed with de novo metastasized hormonal sensitive prostate cancer.
- Trial name
- PET-MaN (NCT05161728)
- Testing
- PSMA-PET/CT
- Where
- 4 sites in Netherlands
- Volunteers
- 150 people
- Sponsor
- Roderick van den Bergh
Prostate Cancer (Adenocarcinoma)
68Ga-AAZTA-NI-093 PET/CT: First-in-human Study
68Ga-AAZTA-093 is a novel radiotracer incorporating a hypoxia sensitive nitroimidazole(NI)-moiety and a PSMA-targeting. In this study, we observed the safety, biodistribution, radiation dosimetry and diagnostic value of…
- Trial name
- NCT06612580
- Testing
- 68Ga-AAZTA-NI-093
- Where
- China
- Volunteers
- 10 people
- Sponsor
- First Affiliated Hospital of Fujian Medical University
Renal Cell Carcinoma
Zirconium-89-girentuximab PET/CT Imaging in Renal Cell Carcinoma
Girentuximab is an antibody against Carbonic Anhydrase IX (CAIX), an antigen that is expressed on the cell surface of 95% of clear cell RCC (ccRCC).
- Trial name
- NCT02883153
- Testing
- Zirconium-89 girentuximab PET/CT
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Prostate Cancer
68Ga-RM2 Compared to 68Ga-PSMA-617 PET/CT for Intermediate Risk Prostate Cancer Imaging
Patients with primary intermediate risk prostate cancer for whom radical prostatectomy is indicated, will be invited to participate to the present study.
- Trial name
- PROSTATEP (NCT03606837)
- Testing
- 68Ga-PSMA-617 PET/CT, 68Ga-RM2 PET/CT
- Where
- France
- Volunteers
- 14 people
- Sponsor
- University Hospital, Bordeaux
Clear Cell Renal Cell Carcinoma
68Ga-NYM096 PET/ CT for the Detection of Clear Cell Renal Cell Carcinoma in Presurgical Patients With Renal Masses
This is a prospective, single-center, single-arm, diagnostic phase 2 study in patients who have renal masses scheduled for surgical resection.
- Trial name
- NCT07101900
- Testing
- 68Ga-NYM096 PET/CT
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Ovarian Neoplasms, Ovarian Cancer
18F-CP18 Imaging Studies for Cancer Treatment With Birinapant
Background: 18F-CP18 is a chemical designed for use in imaging studies. It is attracted to tumor cells that are being killed by cancer treatment.
- Conditions
- Ovarian Neoplasms, Ovarian Cancer, Fallopian Tube Neoplasms, Fallopian Tube Cancer
- Trial name
- NCT01766622
- Testing
- [18F]-CP18, PET/ CT
- Sponsor
- National Institutes of Health Clinical Center (CC)
Cancer
Construction and Clinical Translation of ACE Targeted Nuclear Medicine Imaging Probe
This prospective, single-center, open-label study aims to evaluate the safety, biodistribution, and tumor imaging characteristics of the novel ACE1-targeted PET radiotracer 68Ga-DOTA-BPP in patients with confirmed or suspected…
- Trial name
- NCT06203119
- Testing
- 68Ga-DOTA-BPP, 18F-FDG
- Where
- China
- Volunteers
- 18 people
- Sponsor
- Peking University Cancer Hospital & Institute
HER2 Positive Gastric Cancer
Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System
The positive rate of HER2 in Chinese patients with gastric cancer is about 12-13%. HER2 positive gastric cancer has strong invasion, high metastasis rate and poor prognosis.
- Trial name
- NCT05165602
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Peking University
Cushing s Syndrome
Diagnostic Value of CXCR4-targeted PET/CT in ACTH-dependent and Independent Cushing's Syndrome
In previous clinical practice, 68Ga-Pentixafor PET/CT has demonstrated promising diagnostic utility in various neuroendocrine tumors by targeting CXCR4, a chemokine receptor overexpressed in several ACTH-secreting neoplasms.
- Trial name
- NCT07350707
- Testing
- 68Ga-Pentixafor
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Peking Union Medical College Hospital
Esophageal Squamous Cell Carcinoma
Comparing 61.2 Gy Radiotherapy Dose Versus 50.4 Gy Radiotherapy Dose for Locally Advanced Esophageal Carcinoma
The purpose of this study is to determined the best definitive radiotherapy dosage for patients with locally advanced esophageal squamous cell carcinoma.
- Trial name
- NCT03790553
- Testing
- Radiotherapy
- Where
- 3 sites in China
- Volunteers
- 646 people
- Sponsor
- Fudan University
PET/CT
Evaluation of Attenuation Correction Accuracy in Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)
The purpose of this research proposal is to establish a mechanism to develop tools that will allow the investigators to measure the impact of magnetic resonance (MR) acquisition correction sequences for attenuation correction on…
- Trial name
- NCT03423407
- Testing
- Positron Emission Tomography-Magnetic Resonance Imaging (PET-MRI)
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Myositis, Idiopathic Inflammatory Myopathies
Characterizing Myositis With 68Ga-FAPI PET/CT
To evaluate the potential usefulness of 68Ga-FAPI PET/CT for the diagnosis and evaluation of systemic involvement in idiopathic inflammatory myopathies (IIM)/myositis, and compared the results with those of 18F-FDG PET/CT.
- Trial name
- NCT05952531
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Melanoma
Comparing SLNE With or Without Preoperative Hybrid SPECT/CT in Melanoma
Melanoma has become a growing interdisciplinary problem in public health worldwide. It characteristically disseminates in an orderly progression through lymphatic channels to the regional lymph node and then to more distant…
- Trial name
- NCT03683550
- Testing
- SLNE with preoperative hybrid SPECT/CT, Standard SLNE
- Where
- 13 sites in Germany
- Volunteers
- 836 people
- Sponsor
- University Hospital, Essen
Lung Cancer, Melanoma
PD-L1 Targeting Nanobody Probe for PET Imaging of Solid Tumor
The objective of this study is to construct a noninvasive approach using 68Ga-THP-APN09 PET/CT to detect the PD-L1 expression of tumor lesion in patients with lung cancer, melanoma and other solid tumor to identify patients…
- Conditions
- Lung Cancer, Melanoma, PD-L1, PET/CT
- Trial name
- NCT05156515
- Testing
- 68Ga-THP-APN09
- Where
- China
- Volunteers
- 20 people
- Sponsor
- Peking University Cancer Hospital & Institute
Cervical Cancer
Fludeoxyglucose (FDG) Positron Emission Tomography/Computed Tomography (PET/CT) Cervical Heterogenity Imaging Study
Rationale: Diagnostic procedures, such as positron emission tomography (PET) using fluorodeoxyglucose (FDG), may help determine response to standard cancer therapy in patients with cervical cancer The purpose of this study is to…
- Trial name
- NCT00907140
- Testing
- Positron Emission Tomography
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Washington University School of Medicine
Liver Injury
A Prospective Study of ¹⁸F-DFA PET Imaging for the Assessment of Liver Injury
This study is a prospective exploratory clinical study aimed at evaluating the efficacy (sensitivity, specificity) of 18F-DFA PET imaging in assessing liver function damage.
- Trial name
- NCT07050550
- Where
- China
- Volunteers
- 45 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Locally Advanced Non Small Cell Lung Cancer, Metastatic Non Small Cell Lung Cancer
Local Ablative Stereotactic Radiotherapy for Residual Hypermetabolic Lesion in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer Long-term Responders to Immunotherapy
At present, it is recommended to continue immunotherapy until progression or unacceptable toxicity. However, only a minority of patients benefits from a durable response and most see the disease progress despite several months of…
- Trial name
- TRAILOCLORI01 (NCT05111197)
- Testing
- SRT, Immunotherapy
- Where
- 5 sites in France
- Volunteers
- 112 people
- Sponsor
- Institut Cancerologie de l'Ouest
Neuroendocrine Tumors
68Ga-DOTATOC for Imaging of Neuroendocrine Tumors: Expanded Access Trial
The purpose of this study is to use a new type of scan, called 68Ga-DOTATOC PET/CT scan, instead of OctreoScan, the standard scan, to diagnose, monitor and manage your tumor.
- Trial name
- NCT02358018
- Testing
- 68Ga-DOTATOC PET/CT Scan
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center